AbbVie Announces First Provincial Reimbursements for VENCLEXTA® in Combination with Azacitidine for Acute Myeloid Leukemia Patients Pharmaceutical Investing
Merck to Participate in the 11th Annual SVB Leerink Global Healthcare Conference Life Science Investing
Komo Plant Based Foods to Exhibit at Natural Products Expo West to Develop U.S. Retail Network Life Science Investing
BioHarvest Sciences Inc. Engages Thunder11 as a Public Relations Agency of Record Life Science Investing
Bloom Health Partners CEO Andrew Morton: Data Makes All the Difference in Healthcare Medical Device Investing
Pivotal Phase 3 Data for KEYTRUDA® in High-Risk Early-Stage Triple-Negative Breast Cancer Published in the New England Journal of Medicine Pharmaceutical Investing
Johnson & Johnson to Participate in the Raymond James 43rd Annual Institutional Investors Conference Pharmaceutical Investing
Aurinia Pharmaceuticals to Release Fourth Quarter and Year End 2021 Financial Results on February 28, 2021 Pharmaceutical Investing
Moore Kuehn Encourages GDNSF, NSEC, IDFB, and ADOC Investors to Contact Law Firm Psychedelics Investing
Bristol Myers Squibb Enters Into $5 Billion Aggregate Accelerated Share Repurchase Agreements Pharmaceutical Investing
SHAREHOLDER ALERT: WeissLaw LLP Reminds GDNSF, ATVI, ZNGA, and BRG Shareholders About Its Ongoing Investigations Psychedelics Investing
Marvel Biosciences Reports MB-204 as Highly Effective at Treating Autism Behaviours in Shank3 Mouse Model
